Physician profile
Rodney E Sturgeon
NPI 1891745436
$10,620.19
in general payments reported to CMS, 2019-2025
44 companies · $2,186 in 2025
The $2,186 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,748 · 2020: $801 · 2021: $1,057 · 2022: $1,347 · 2023: $1,726 · 2024: $1,756 · 2025: $2,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,479 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,478.89 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,415.49 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $1,266.87 | 2019-2025 | |
| Abbvie INC. | $1,261.11 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,080.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $767.42 | 2019-2025 | Xifaxan |
| Amgen INC. | $667.51 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $552.21 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $510.66 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $498.36 | 2019-2025 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $359.03 | 2021-2025 | |
| Lilly USA, LLC | $239.60 | 2019-2025 | Jardiance, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $207.17 | 2021-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $182.15 | 2019-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $178.06 | 2019-2024 | Trintellix |
| Xeris Pharmaceuticals, INC. | $158.75 | 2023-2024 | Gvoke Hypopen |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Sturgeon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.